Alexander M Lesokhin
Overview
Explore the profile of Alexander M Lesokhin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
7963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan C, Wang A, Nemirovsky D, Derkach A, Shekarkhand T, Hamadeh I, et al.
Blood Adv
. 2025 Mar;
PMID: 40048741
No abstract available.
2.
Fei T, Donovan V, Funnell T, Baichoo M, Waters N, Paredes J, et al.
bioRxiv
. 2025 Mar;
PMID: 40027751
Correlating time-dependent patient characteristics and matched microbiome samples can be helpful to identify biomarkers in longitudinal microbiome studies. Existing approaches typically repeat a pre-specified modeling approach for all taxonomic features,...
3.
Jurgens E, Firestone R, Chaudhari J, Hosszu K, Devlin S, Shah U, et al.
J Clin Oncol
. 2024 Dec;
43(5):498-504.
PMID: 39631041
MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical...
4.
Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, et al.
Blood Cancer J
. 2024 Sep;
14(1):164.
PMID: 39300066
No abstract available.
5.
Maura F, Kaddoura M, Poos A, Baughn L, Ziccheddu B, Bartsch M, et al.
bioRxiv
. 2024 Sep;
PMID: 39282268
To comprehensively unravel the temporal relationship between initiating and driver events and its impact on clinical outcomes, we analyzed 421 whole-genome sequencing profiles from 382 patients. Using clock-like mutational signatures,...
6.
Richard S, Lesokhin A, Paul B, Kaufman J, Pianko M, Biran N, et al.
Nat Cancer
. 2024 Aug;
5(10):1459-1464.
PMID: 39187595
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and...
7.
Pak W, Brumwell N, Kabel C, Gutgarts V, Sathick I, Mailankody S, et al.
Kidney Med
. 2024 Aug;
6(8):100856.
PMID: 39100867
Chimeric antigen receptor (CAR) T-cell therapy against B-cell maturation antigen is a new treatment modality for relapsed or refractory multiple myeloma (MM). Patients with kidney failure and MM were excluded...
8.
Tomasson M, Iida S, Niesvizky R, Mohty M, Bahlis N, Martinez-Lopez J, et al.
Hemasphere
. 2024 Jul;
8(7):e136.
PMID: 39055646
No abstract available.
9.
Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, et al.
Res Sq
. 2024 Jun;
PMID: 38883739
Lenalidomide maintenance is associated with a significantly improved progression-free in patients with newly diagnosed multiple myeloma. Maintenance with lenalidomide is generally well tolerated; however, lenalidomide associated diarrhea is a common...
10.
Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa B, Nishimura N, et al.
Blood Cancer J
. 2024 May;
14(1):88.
PMID: 38821925
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell...